Search

Your search keyword '"Barbaud A"' showing total 50 results
Start Over Author "Barbaud A" Publication Year Range Last 50 years Journal allergy
50 results on '"Barbaud A"'

2. Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper

Author

Bavbek, Sevim, primary, Kepil Özdemir, Seçil, additional, Bonadonna, Patrizia, additional, Atanaskovic‐Markovic, Marina, additional, Barbaud, Annick, additional, Brockow, Knut, additional, Laguna Martinez, Jose, additional, Nakonechna, Alla, additional, Pagani, Mauro, additional, Arcolacı, Alessandra, additional, Lombardo, Carla, additional, and Torres, Maria J., additional

Published
2023
Full Text
View/download PDF

3. EAACI/ENDA position paper on drug provocation testing.

Author

Barbaud, Annick, Garvey, Lene Heise, Torres, Maria, Laguna, Jose Julio, Arcolaci, Alessandra, Bonadonna, Patrizia, Scherer Hofmeier, Kathrin, Chiriac, Anca Mirela, Cernadas, Josefina, Caubet, Jean Christoph, and Brockow, Knut

Subjects
*BETA lactam antibiotics, *SKIN tests, *DRUG allergy, *CONTRAST media, *PROTON pump inhibitors
Abstract

In drug hypersensitivity, drug provocation testing (DPT), also called drug challenge, is the gold standard for investigation. In recent years, risk stratification has become an important tool for adjusting the diagnostic strategy to the perceived risk, whilst still maintaining a high level of safety for the patient. Skin tests are recommended before DPT but may be omitted in low‐risk patients. The task force suggests a strict definition of such low‐risk patients in children and adults. Based on experience and evidence from studies of allergy to beta‐lactam antibiotics, an algorithm on how to adjust DPT to the risk, and when to omit skin tests before DPT, is presented. For other antibiotics, non‐steroidal anti‐inflammatory drugs and other drugs, skin tests are poorly validated and DPT is frequently necessary. We recommend performing DPT with chemotherapeutics and biologicals to avoid unnecessary desensitization procedures and DPT with skin tests negative contrast media. We suggest DPT with anesthetics only in highly specialized centers. Specifics of DPT to proton pump inhibitors, anticonvulsants and corticosteroids are discussed. This position paper provides general recommendations and guidance on optimizing use of DPT, whilst balancing benefits with patient safety and optimizing the use of the limited available resources. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper.

Author

Bavbek, Sevim, Kepil Özdemir, Seçil, Bonadonna, Patrizia, Atanaskovic‐Markovic, Marina, Barbaud, Annick, Brockow, Knut, Laguna Martinez, Jose, Nakonechna, Alla, Pagani, Mauro, Arcolacı, Alessandra, Lombardo, Carla, and Torres, Maria J.

Subjects
PROTON pump inhibitors, DELAYED hypersensitivity, FOOD allergy, ALLERGIES, MEDICAL personnel
Abstract

Proton pump inhibitors (PPIs) are invaluable therapeutic options in a variety of dyspeptic diseases. In addition to their well‐known risk profile, PPI consumption is related to food and environmental allergies, dysbiosis, osteoporosis, as well as immediate and delayed hypersensitivity reactions (HSRs). The latter, although a rare event, around 1%–3%, due to the extraordinarily high rate of prescription and consumption of PPIs are related to a substantial risk. In this Position Paper, we provide clinicians with practical evidence‐based recommendations for the diagnosis and management of HSRs to PPIs. Furthermore, the unmet needs proposed in the document aim to stimulate more in‐depth investigations in the topic. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Flow‐based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper.

Author

Mayorga, C., Çelik, G. E., Pascal, M., Hoffmann, H. J., Eberlein, B., Torres, M. J., Brockow, K., Garvey, L. H., Barbaud, A., Madrigal‐Burgaleta, R., Caubet, J. C., and Ebo, D. G.

Subjects
DRUG allergy, ALLERGIES, TASK forces, NEUROMUSCULAR blocking agents, BASOPHILS
Abstract

Diagnosing immediate drug hypersensitivity reactions (IDHRs) can pose a significant challenge and there is an urgent need for safe and reliable tests. Evidence has emerged that the basophil activation test (BAT), an in vitro assay that mirrors the in vivo response, can be a complementary test for many drugs. In this position paper, members of Task Force (TF) "Basophil activation test in the evaluation of Drug Hypersensitivity Reactions" from the European Academy of Allergy and Clinical Immunology (EAACI) present the data from a survey about the use and utility of BAT in IDHRs in Europe. The survey results indicate that there is a great interest for using BAT especially for diagnosing IDHRs. However, there are still main needs, mainly in the standardization of the protocols. Subsequently consensus‐based recommendations were formulated for: (i) Technical aspects of BAT in IDHRs including type of sample, management of drugs, flow cytometry protocols, interpretation of the results; and (ii) Drug‐specific aspects that should be taken into account when performing BAT in relation to betalactams, neuromuscular blocking agents, fluoroquinolones, chlorhexidine, opioids, radio contrast media, chemotherapeutics, biological agents, nonsteroidal anti‐inflammatory drugs, COVID vaccine, and excipients. Moreover, aspects in the evaluation of pediatric population have also been considered. All this indicates that BAT offers the clinician and laboratory a complementary tool for a safe diagnostic for IDHRs, although its place in the diagnostic algorithm depends on the drug class and patient population (phenotype, geography, and age). The standardization of BAT is important for generalizing this method beyond the individual laboratory. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Management of anaphylaxis due to COVID-19 vaccines in the elderly

Author

Paulo Augusto Moreira Camargos, Radolslaw Gawlik, Mirko Petrovic, Gunter J. Sturm, Kristof Nekam, Sergio Bonini, Zhanat Ispayeva, Marilyn Urrutia Pereira, Jean Bousquet, Antti Lauerma, Menachem Rottem, Arzu Yorgancioglu, Hubert Blain, Antonio Cherubini, Mário Morais-Almeida, Nathalie Salles, Charlotte G. Mortz, Sylwia Smolinska, Davor Plavec, A. Bedbrook, Torsten Zuberbier, Helga Kraxner, M. Beatrice Bilò, Sinthia Bosnic-Anticevich, Gaëtan Gavazzi, Finbarr C. Martin, Alvaro A. Cruz, K. S. Bennoor, Isabella Annesi-Maesano, Mohamed H. Shamji, Karin Hoffmann-Sommergruber, Marina Atanaskovic-Markovic, Carsten Bindslev-Jensen, Lan Tt Le, Isabel Skypala, Ana Todo-Bom, Vincenzo Patella, Lorenzo Cecchi, Charlotte Suppli Ulrik, Oscar Palomares, Joaquin Sastre, Hans Jürgen Hoffmann, Knut Brockow, Eva Untersmayr, Martin Hrubisko, Bernadette Eberlein, Aziz Sheikh, Milan Sova, Osman M. Yusuf, Violeta Kvedariene, G. Walter Canonica, Dana Wallace, Ioana Agache, Milena Sokolowska, Jos M. G. A. Schols, Susan Waserman, Stéphanie Miot, Carla Irani, Regina E Roller-Winsberger, Michael Levin, Yves Rolland, Emma Montella, Bilun Gemicioglu, Bolesław Samoliński, Stefano Del Giacco, Madda lenaIllario, Yehia El-Gamal, Olga Lourenço, Jean-Christoph Roger J-P Caubet, Luisa Brussino, Marysia Recto, De Yun Wang, Igor Kaidashev, Renaud Louis, Antonino Romano, Mario E. Zernotti, Jacques Reynes, Pedro Carreiro-Martins, Alexandra F. Santos, Marek Niedoszytko, M. Gotua, Musa Khaitov, Thomas B. Casale, Andrea Matucci, Bernardo Sousa-Pinto, Rafael Stelmach, Dejan Dokic, Joana Vitte, Motohiro Ebisawa, Maria Teresa Ventura, Joaquim Mullol, Tomas Chivato, Petr Panzner, Oliver Pfaar, Sanna Toppila-Salmi, Ioanna Tsiligianni, Wytske Fokkens, Alessandra Vultaggio, H. Neffen, Juan Carlos Ivancevich, Ya-dong Gao, Anna Sediva, Maja Hofmann, Ana Maria Carriazo, João Fonseca, Marek Jutel, A. Benetos, Nhân Pham-Thi, Mona Al-Ahmad, Arunas Valiulis, Mihaela Zidarn, Elizabeth Angier, Yoshitaka Okamoto, Montserrat Fernandez-Rivas, Cezmi A. Akdis, Philip W. Rouadi, Olivier Guérin, John Farrell, Mikaela Odemyr, George Christoff, Vera Mahler, Claus Bachert, Edward F. Knol, Wienczyslawa Czarlewski, Robyn E O'Hehir, Victoria Cardona, Ludger Klimek, Tari Haahtela, Vincent Le Moing, Branislava Milenkovic, Carmen Rondon, Kaja Julge, Jolanta Walusiak-Skorupa, Nikolaos G. Papadopoulos, Aslı Gelincik, Markus Ollert, Piotr Kuna, Leyla Namazova-Baranova, Margitta Worm, Annick Barbaud, Elena Camelia Berghea, Todor A. Popov, Derek K. Chu, María José Torres, Faradiba Sarquis Serpa, Nicola Scichilone, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Gianni Passalacqua, Humboldt-Universität zu Berlin, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Humboldt University Of Berlin, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Transylvania University, Wrocław Medical University, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Cagliari, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Università Politecnica delle Marche [Ancona] (UNIVPM), Medical Consulting Czarlewski, Universiti Putra Malaysia, University of Southampton, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Belgrade [Belgrade], Ghent University Hospital, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Dhaka Shishu Hospital [Bangladesh], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Odense University Hospital (OUH), Italian National Research Council, National Research Council [Italy] (CNR), The University of Sydney, Technische Universität München = Technical University of Munich (TUM), Università degli studi di Torino = University of Turin (UNITO), Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), IRCCS Research Hospital, Milan, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, University of South Florida [Tampa] (USF), Geneva University Hospital (HUG), Azienda Usl Toscana centro [Firenze], Софийски университет = Sofia University, McMaster University [Hamilton, Ontario], State University of Bahia, Institute of Public Health of Republic of North Macedonia [Skopje], Ain Shams University (ASU), Sagamihara National Hospital [Kanagawa, Japan], Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Amsterdam UMC - Amsterdam University Medical Center, Universidade do Porto = University of Porto, Wuhan University [China], CHU Grenoble, Silesian University of Medicine, Istanbul Faculty of Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Centre Hospitalier Universitaire de Nice (CHU Nice), Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Medizinische Universität Wien = Medical University of Vienna, Aarhus University [Aarhus], Oncology Institute of St Elisabeth, University of Naples Federico II = Università degli studi di Napoli Federico II, St Joseph University, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Kazakh National Medical University, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Tartu University Institute of Clinical Medicine, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Federal Medicobiological Agency [Moscow, Russian Federation], University Medical Center [Utrecht], Semmelweis University [Budapest], Medical University of Łódź (MUL), Vilnius University [Vilnius], University of Medicine and Pharmacy (VIETNAM), University of Cape Town, CHU Sart Tilman, Université de Liège, University of Beira Interior [Portugal] (UBI), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, CHU Montpellier, Wroclaw Medical University [Wrocław, Pologne], University of Bari Aldo Moro (UNIBA), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sagamihara National Hospital, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Toulouse [Toulouse], RS: CAPHRI - R1 - Ageing and Long-Term Care, Health Services Research, Bousquet J., Agache I., Blain H., Jutel M., Ventura M.T., Worm M., Del Giacco S., Benetos A., Bilo B.M., Czarlewski W., Abdul Latiff A.H., Al-Ahmad M., Angier E., Annesi-Maesano I., Atanaskovic-Markovic M., Bachert C., Barbaud A., Bedbrook A., Bennoor K.S., Berghea E.C., Bindslev-Jensen C., Bonini S., Bosnic-Anticevich S., Brockow K., Brussino L., Camargos P., Canonica G.W., Cardona V., Carreiro-Martins P., Carriazo A., Casale T., Caubet J.-C., Cecchi L., Cherubini A., Christoff G., Chu D.K., Cruz A.A., Dokic D., El-Gamal Y., Ebisawa M., Eberlein B., Farrell J., Fernandez-Rivas M., Fokkens W.J., Fonseca J.A., Gao Y., Gavazzi G., Gawlik R., Gelincik A., Gemicioglu B., Gotua M., Guerin O., Haahtela T., Hoffmann-Sommergruber K., Hoffmann H.J., Hofmann M., Hrubisko M., Illario M., Irani C., Ispayeva Z., Ivancevich J.C., Julge K., Kaidashev I., Khaitov M., Knol E., Kraxner H., Kuna P., Kvedariene V., Lauerma A., Le L.T.T., Le Moing V., Levin M., Louis R., Lourenco O., Mahler V., Martin F.C., Matucci A., Milenkovic B., Miot S., Montella E., Morais-Almeida M., Mortz C.G., Mullol J., Namazova-Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Okamoto Y., Ollert M., Palomares O., Papadopoulos N.G., Panzner P., Passalacqua G., Patella V., Petrovic M., Pfaar O., Pham-Thi N., Plavec D., Popov T.A., Recto M.T., Regateiro F.S., Reynes J., Roller-Winsberger R.E., Rolland Y., Romano A., Rondon C., Rottem M., Rouadi P.W., Salles N., Samolinski B., Santos A.F., S Sarquis F., Sastre J., M. G. A. Schols J., Scichilone N., Sediva A., Shamji M.H., Sheikh A., Skypala I., Smolinska S., Sokolowska M., Sousa-Pinto B., Sova M., Stelmach R., Sturm G., Suppli Ulrik C., Todo-Bom A.M., Toppila-Salmi S., Tsiligianni I., Torres M., Untersmayr E., Urrutia Pereira M., Valiulis A., Vitte J., Vultaggio A., Wallace D., Walusiak-Skorupa J., Wang D.-Y., Waserman S., Yorgancioglu A., Yusuf O.M., Zernotti M., Zidarn M., Chivato T., Akdis C.A., Zuberbier T., Klimek L., HUS Inflammation Center, University of Helsinki, and Department of Dermatology, Allergology and Venereology

Subjects
Male, Allergy, Pediatrics, Eaaci Position Paper, COVID-19 vaccines, older (adults, GUIDELINES, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine and Health Sciences, Immunology and Allergy, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Geriatrics, MESH: Aged, RISK, Vaccines, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, people), EPINEPHRINE, Epinephrine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, COVID -19 vaccines, Anaphylaxis, medicine.drug, older (adults/people), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), MESH: Covid-19, MESH: Epinephrine, Immunology, adrenaline, anaphylaxis, Aged, COVID-19 Vaccines, Humans, SARS-CoV-2, COVID-19, Settore MED/10 - Malattie Dell'Apparato Respiratorio, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diabetes mellitus, Anaphylaxis/etiology, MESH: SARS-CoV-2, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, COVID‐19 vaccines, Older - Adults/people, Asthma, MESH: Humans, business.industry, adrenaline, anaphylaxis, COVID-19 vaccines, older (adults/people), medicine.disease, Obesity, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, MESH: Male, MESH: Anaphylaxis, Older, 3121 General medicine, internal medicine and other clinical medicine, business, MESH: Covid-19 vaccines, 030215 immunology
Abstract

Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:34:51Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:35:49Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Made available in DSpace on 2021-07-05T13:35:49Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Previous issue date: 2021-04-02 info:eu-repo/semantics/publishedVersion

Published
2021

7. Risk stratification through extensive allergy work‐up in COVID‐19‐mRNA vaccine allergic reactions

Author

Soria, Angèle, primary, Labella, Marina, additional, Doña, Inmaculada, additional, Nicaise‐Roland, Pascale, additional, Chollet‐Martin, Sylvie, additional, Autegarden, Jean‐Eric, additional, Castagna, Julie, additional, Le Thai, Claire, additional, de Chaisemartin, Luc, additional, Torres, Maria José, additional, and Barbaud, Annick, additional

Published
2023
Full Text
View/download PDF

9. Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti‐inflammatory drug hypersensitivity

Author

Cortellini, G., Romano, A., Santucci, A., Barbaud, A., Bavbek, S., Bignardi, D., Blanca, M., Bonadonna, P., Costantino, M. T., Laguna, J. J., Lombardo, C., Losappio, L.M., Makowska, J., Nakonechna, A., Quercia, O., Pastorello, E. A., Patella, V., Terreehorst, I., Testi, S., Cernadas, J. R., Dionicio Elera, J., Lippolis, D., Voltolini, S., and Grosseto, D.

Published
2017
Full Text
View/download PDF

10. Allergies and COVID‐19 vaccines: An ENDA/EAACI Position paper

Author

Barbaud, Annick, primary, Garvey, Lene Heise, additional, Arcolaci, Alessandra, additional, Brockow, Knut, additional, Mori, Francesca, additional, Mayorga, Cristobalina, additional, Bonadonna, Patrizia, additional, Atanaskovic‐Markovic, Marina, additional, Moral, Luis, additional, Zanoni, Giovanna, additional, Pagani, Mauro, additional, Soria, Angèle, additional, Jošt, Maja, additional, Caubet, Jean‐Christoph, additional, Carmo, Abreu, additional, Mona, Al‐Ahmad, additional, Alvarez‐Perea, Alberto, additional, Bavbek, Sevim, additional, Benedetta, Biagioni, additional, Bilo, M.Beatrice, additional, Blanca‐López, Natalia, additional, Bogas, Herrera Gádor, additional, Buonomo, Alessandro, additional, Calogiuri, Gianfranco, additional, Carli, Giulia, additional, Cernadas, Josefina, additional, Cortellini, Gabriele, additional, Celik, Gülfem, additional, Demir, Semra, additional, Doña, Inmaculada, additional, Dursun, Adile Berna, additional, Eberlein, Bernadette, additional, Faria, Emilia, additional, Fernandes, Bryan, additional, Garcez, Tomaz, additional, Garcia‐Nunez, Ignacio, additional, Gawlik, Radoslaw, additional, Gelincik, Asli, additional, Gomes, Eva, additional, Gooi, Jimmy H. C., additional, Grosber, Martine, additional, Gülen, Theo, additional, Hacard, Florence, additional, Hoarau, Cyrille, additional, Janson, Christer, additional, Johnston, Sebastian L., additional, Joerg, Lukas, additional, Kepil Özdemir, Seçil, additional, Klimek, Ludger, additional, Košnik, Mitja, additional, Kowalski, Marek L., additional, Kuyucu, Semanur, additional, Kvedariene, Violeta, additional, Laguna, Jose Julio, additional, Lombardo, Carla, additional, Marinho, Susana, additional, Merk, Hans, additional, Meucci, Elisa, additional, Morisset, Martine, additional, Munoz‐Cano, Rosa, additional, Murzilli, Francesco, additional, Nakonechna, Alla, additional, Popescu, Florin‐Dan, additional, Porebski, Grzegorz, additional, Radice, Anna, additional, Regateiro, Frederico S., additional, Röckmann, Heike, additional, Romano, Antonino, additional, Sargur, Ravishankar, additional, Sastre, Joaquin, additional, Scherer Hofmeier, Kathrin, additional, Sedláčková, Lenka, additional, Sobotkova, Marta, additional, Terreehorst, Ingrid, additional, Treudler, Regina, additional, Walusiak‐Skorupa, Jolanta, additional, Wedi, Bettina, additional, Wöhrl, Stefan, additional, Zidarn, Mihael, additional, Zuberbier, Torsten, additional, Agache, Ioana, additional, and Torres, Maria J., additional

Published
2022
Full Text
View/download PDF

11. Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

Author

Antonino Romano, Knut Brockow, Cristobalina Mayorga, María José Torres, Gülfem Çelik, Aslı Gelincik, Marina Atanaskovic-Markovic, Annick Barbaud, Ozge Soyer, and Inmaculada Doña

Subjects
Drug, medicine.medical_specialty, SARS‐CoV2, medicine.medical_treatment, media_common.quotation_subject, Immunology, desensitization, Review Article, Disease, medicine.disease_cause, Asymptomatic, Drug Hypersensitivity, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, COVID‐19, Pandemic, medicine, Humans, Immunology and Allergy, drug hypersensitivity reactions, Intensive care medicine, Pandemics, Review Articles, Coronavirus, Desensitization (medicine), media_common, SARS-CoV-2, business.industry, Academies and Institutes, COVID-19, 3. Good health, Europe, 030228 respiratory system, Position paper, Differential diagnosis, medicine.symptom, business
Abstract

Coronavirus disease 2019 (COVID‐19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID‐19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off‐label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings togetherall the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off‐label drugs andhighlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactionsin the course of the disease.

Published
2020

12. Management of anaphylaxis due to COVID‐19 vaccines in the elderly

Author

Bousquet, Jean, primary, Agache, Ioana, additional, Blain, Hubert, additional, Jutel, Marek, additional, Ventura, Maria Teresa, additional, Worm, Margitta, additional, Del Giacco, Stefano, additional, Benetos, Athanasios, additional, Bilo, Beatrice Maria, additional, Czarlewski, Wienczyslawa, additional, Abdul Latiff, Amir Hamzah, additional, Al‐Ahmad, Mona, additional, Angier, Elizabeth, additional, Annesi‐Maesano, Isabella, additional, Atanaskovic‐Markovic, Marina, additional, Bachert, Claus, additional, Barbaud, Annick, additional, Bedbrook, Anna, additional, Bennoor, Kazi S., additional, Berghea, Elena Camelia, additional, Bindslev‐Jensen, Carsten, additional, Bonini, Sergio, additional, Bosnic‐Anticevich, Sinthia, additional, Brockow, Knut, additional, Brussino, Luisa, additional, Camargos, Paulo, additional, Canonica, G. Walter, additional, Cardona, Victoria, additional, Carreiro‐Martins, Pedro, additional, Carriazo, Ana, additional, Casale, Thomas, additional, Caubet, Jean‐Christoph, additional, Cecchi, Lorenzo, additional, Cherubini, Antonio, additional, Christoff, George, additional, Chu, Derek K., additional, Cruz, Alvaro A., additional, Dokic, Dejan, additional, El‐Gamal†, Yehia, additional, Ebisawa, Motohiro, additional, Eberlein, Bernadette, additional, Farrell, John, additional, Fernandez‐Rivas, Montserrat, additional, Fokkens, Wytske J., additional, Fonseca, Joao A., additional, Gao, Yadong, additional, Gavazzi, Gaëtan, additional, Gawlik, Radoslaw, additional, Gelincik, Asli, additional, Gemicioğlu, Bilun, additional, Gotua, Maia, additional, Guérin, Olivier, additional, Haahtela, Tari, additional, Hoffmann‐Sommergruber, Karin, additional, Hoffmann, Hans Jürgen, additional, Hofmann, Maja, additional, Hrubisko, Martin, additional, Illario, Maddalena, additional, Irani, Carla, additional, Ispayeva, Zhanat, additional, Ivancevich, Juan Carlos, additional, Julge, Kaja, additional, Kaidashev, Igor, additional, Khaitov, Musa, additional, Knol, Edward, additional, Kraxner, Helga, additional, Kuna, Piotr, additional, Kvedariene, Violeta, additional, Lauerma, Antti, additional, Le, Lan T. T., additional, Le Moing, Vincent, additional, Levin, Michael, additional, Louis, Renaud, additional, Lourenco, Olga, additional, Mahler, Vera, additional, Martin, Finbarr C., additional, Matucci, Andrea, additional, Milenkovic, Branislava, additional, Miot, Stéphanie, additional, Montella, Emma, additional, Morais‐Almeida, Mario, additional, Mortz, Charlotte G., additional, Mullol, Joaquim, additional, Namazova‐Baranova, Leyla, additional, Neffen, Hugo, additional, Nekam, Kristof, additional, Niedoszytko, Marek, additional, Odemyr, Mikaëla, additional, O’Hehir, Robyn E., additional, Okamoto, Yoshitaka, additional, Ollert, Markus, additional, Palomares, Oscar, additional, Papadopoulos, Nikolaos G., additional, Panzner, Petr, additional, Passalacqua, Giovanni, additional, Patella, Vincenzo, additional, Petrovic, Mirko, additional, Pfaar, Oliver, additional, Pham‐Thi, Nhân, additional, Plavec, Davor, additional, Popov, Todor A., additional, Recto, Marysia T., additional, Regateiro, Frederico S., additional, Reynes, Jacques, additional, Roller‐Winsberger, Regina E., additional, Rolland, Yves, additional, Romano, Antonino, additional, Rondon, Carmen, additional, Rottem, Menachem, additional, Rouadi, Philip W., additional, Salles, Nathalie, additional, Samolinski, Boleslaw, additional, Santos, Alexandra F., additional, S Sarquis, Faradiba, additional, Sastre, Joaquin, additional, M. G. A. Schols, Jos, additional, Scichilone, Nicola, additional, Sediva, Anna, additional, Shamji, Mohamed H., additional, Sheikh, Aziz, additional, Skypala, Isabel, additional, Smolinska, Sylwia, additional, Sokolowska, Milena, additional, Sousa‐Pinto, Bernardo, additional, Sova, Milan, additional, Stelmach, Rafael, additional, Sturm, Gunter, additional, Suppli Ulrik, Charlotte, additional, Todo‐Bom, Ana Maria, additional, Toppila‐Salmi, Sanna, additional, Tsiligianni, Ioanna, additional, Torres, Maria, additional, Untersmayr, Eva, additional, Urrutia Pereira, Marilyn, additional, Valiulis, Arunas, additional, Vitte, Joana, additional, Vultaggio, Alessandra, additional, Wallace, Dana, additional, Walusiak‐Skorupa, Jolanta, additional, Wang, De‐Yun, additional, Waserman, Susan, additional, Yorgancioglu, Arzu, additional, Yusuf, Osman M., additional, Zernotti, Mario, additional, Zidarn, Mihaela, additional, Chivato, Tomas, additional, Akdis, Cezmi A., additional, Zuberbier, Torsten, additional, and Klimek, Ludger, additional

Published
2021
Full Text
View/download PDF

13. Allergological workup with half-dose challenge in iodinated contrast media hypersensitivity

Author

J.E. Autegarden, Amandine Vial-Dupuy, Angèle Soria, H. Gaouar, Sylvie Chollet-Martin, Annick Barbaud, Pascale Nicaise-Roland, Nathalie Masson, and Emmanuelle Amsler

Subjects
0301 basic medicine, medicine.medical_specialty, business.industry, Immunology, Iodine Compounds, Contrast Media, Disease Management, Allergens, Dermatology, Drug Hypersensitivity, Iodinated contrast media, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030228 respiratory system, Humans, Immunology and Allergy, Medicine, Disease management (health), business, Skin Tests
Published
2018

14. Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity

Author

Torres, María José, primary, Trautmann, Axel, additional, Böhm, Ingrid, additional, Scherer, Kathrin, additional, Barbaud, Annick, additional, Bavbek, Sevim, additional, Bonadonna, Patrizia, additional, Cernadas, Josefina Rodrigues, additional, Chiriac, Anca Mirela, additional, Gaeta, Francesco, additional, Gimenez‐Arnau, Ana M., additional, Kang, Hye‐Ryun, additional, Moreno, Esther, additional, and Brockow, Knut, additional

Published
2021
Full Text
View/download PDF

16. Towards a more precise diagnosis of hypersensitivity to beta‐lactams — an EAACI position paper

Author

Romano, Antonino, primary, Atanaskovic‐Markovic, Marina, additional, Barbaud, Annick, additional, Bircher, Andreas J., additional, Brockow, Knut, additional, Caubet, Jean‐Christoph, additional, Celik, Gulfem, additional, Cernadas, Josefina, additional, Chiriac, Anca‐Mirela, additional, Demoly, Pascal, additional, Garvey, Lene H., additional, Mayorga, Cristobalina, additional, Nakonechna, Alla, additional, Whitaker, Paul, additional, and Torres, María José, additional

Published
2020
Full Text
View/download PDF

17. First evidence of occupational asthma to argan powder in a cosmetic factory

Author

Isabelle Thaon, Fabrice Herin, Mathias Poussel, Emmanuelle Penven, Christelle Richard, Christophe Paris, S Jacquenet, A. Barbaud, Centre de consultations de pathologies professionnelles [CHRU Nancy] (CCPP), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Interactions Gènes-Risques environnementaux et Effets sur la Santé (INGRES), Université de Lorraine (UL), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de consultations de pathologies professionnelles [CHU Toulouse], CHU Toulouse [Toulouse], Université Fédérale Toulouse Midi-Pyrénées, Genclis SAS, Service de Dermatologie et Allergologie [CHRU Nancy], Développement, Adaptation et Handicap. Régulations cardio-respiratoires et de la motricité (DevAH), and Service des examens de la Fonction respiratoire et de l’aptitude à l’exercice [CHRU Nancy]

Subjects
Adult, Male, Allergy, medicine.medical_specialty, Probable Case, media_common.quotation_subject, Immunology, Occupational disease, Cosmetics, Bronchial Provocation Tests, 03 medical and health sciences, Specific inhalation challenge, 0302 clinical medicine, Risk Factors, Occupational Exposure, medicine, Humans, Immunology and Allergy, Asthma, Occupational, Skin Tests, media_common, Sapotaceae, 030201 allergy, Traditional medicine, business.industry, Allergens, Antigens, Plant, Immunoglobulin E, Middle Aged, medicine.disease, 11s globulin, Elisa inhibition, 3. Good health, Surgery, 030228 respiratory system, Female, business, Occupational asthma, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; BackgroundArgan is used worldwide in numerous cosmetic products, as this fruit is supposed to have many beneficial properties on health. New cases of allergy can be expected with the growing use of argan. We investigated all workers (9) employed by a cosmetic factory and exposed to argan powder to identify possible allergies related to exposure to argan powder.MethodsPatients were investigated in the occupational disease department and, according to their symptoms, underwent pulmonary function testing, methacholine challenge, specific inhalation challenge to argan powder, skin prick tests, and immunoblotting analysis.ResultsWe report three cases of occupational asthma to argan powder and a probable case of rhinitis. Fifteen argan proteins were recognized by the patients' IgE. Identification of proteins, cross-reactions to nuts, and ELISA inhibition tests suggested that some argan allergens can cross-react in vitro with hazelnut allergens, including 11S globulin and vicilin.ConclusionHigh-level exposure to argan powder should be considered to be a potential cause of IgE-mediated allergy, and workers handling argan powder should be carefully investigated.

Published
2016

18. Genetic variants associated with drugs-induced immediate hypersensitivity reactions: a PRISMA-compliant systematic review

Author

Ingrid Terreehorst, Jean-Christoph Roger J-P Caubet, Luciana Kase Tanno, Josefina Cernadas, M. Gotua, M. Atanaskovic, Pascal Demoly, M. Blanca, Abderrahim Oussalah, Alla Nakonechna, Andreas J. Bircher, A. Barbaud, Antonino Romano, Jose Julio Laguna, Knut Brockow, Cristobalina Mayorga, Jean-Louis Guéant, Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service de Biochimie et Biologie Moléculaire, Nutrition et Métabolisme [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Biomedical Research Institute of Málaga (IBIMA), Service de Dermatologie et Allergologie [CHRU Nancy], Allergy and Immunology Clinic [Royal Liverpool and Broadgreen University Hospital], Royal Liverpool and Broadgreen University Hospital NHS Trust, Immunoallergy Department [Porto], Centro Hospitalar São João EPE, Center for Allergy and Immunology Research [Tbilisi], Department of Dermatology and Allergy Biederstein, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Division of Paediatrics [Geneva], University Hospital of Geneva, University Hospital Basel [Basel], Department of Allergology and Pulmonology [Belgrade], University Children's Hospital [Belgrade], Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Hospital Sírio-Libanês [São Paulo, Brazil], Academisch Medisch Centrum bij, Universiteit van Amsterdam (UvA), Allergy Unit [Cruz Roja-Madrid], Hospital Central de la Cruz Roja San Jose y Santa Adela, and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)

Subjects
Hypersensitivity, Immediate, Candidate gene, [SDV]Life Sciences [q-bio], Immunology, Human leukocyte antigen, Drug Hypersensitivity, Atopy, 03 medical and health sciences, 0302 clinical medicine, Genetic variation, Genetic predisposition, medicine, Humans, Immunology and Allergy, Genetic Predisposition to Disease, 030212 general & internal medicine, Allele frequency, Aspirin, ddc:618, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Nonsteroidal anti-inflammatory drugs, Genetic Variation, Environmental exposure, Immunoglobulin E, medicine.disease, Anti-Bacterial Agents, 3. Good health, Beta-lactam antibiotics, 030228 respiratory system, Genetic predictors, IgE-mediated drug allergy, business, medicine.drug
Abstract

International audience; Drug hypersensitivity includes allergic (AR) and nonallergic reactions (NARs) influenced by genetic predisposition. We performed a systematic review of genetic predictors of IgE-mediated AR and NAR with MEDLINE and PubMed search engine between January 1966 and December 2014. Among 3110 citations, the search selected 53 studies, 42 of which remained eligible. These eligible studies have evaluated genetic determinants of immediate reactions (IR) to beta-lactams (n = 19), NAR against aspirin (n = 12) and other nonsteroidal anti-inflammatory drugs (NSAIDs) (n = 8), and IR to biologics (n = 3). We reported two genomewide association studies and four case–control studies on candidate genes validated by replication. Genes involved in IR to beta-lactams belonged to HLA type 2 antigen processing, IgE production, atopy, and inflammation, including 4 genes validated by replications, HLA-DRA, ILR4, NOD2, and LGALS3. Genes involved in NAR to aspirin belonged to arachidonic acid pathway, membrane-spanning 4A gene family, histamine production pathway, and pro-inflammatory cytokines, while those involved in NAR to all NSAIDs belonged to arachidonic acid pathway and HLA antigen processing pathway. ALOX5 was a common predictor of studies on NAR to both aspirin and NSAIDs. Although these first conclusions could be drawn, this review highlights also the lack of reliable data and the need for replicating studies in contrasted populations, taking into account worldwide allele frequencies, gene–gene interactions, and contrasted situations of environmental exposure.

Published
2016

19. A EAACI drug allergy interest group survey on how European allergy specialists deal with β-lactam allergy

Author

Torres, Maria Jose, primary, Celik, Gulfem Elif, additional, Whitaker, Paul, additional, Atanaskovic-Markovic, Marina, additional, Barbaud, Annick, additional, Bircher, Andreas, additional, Blanca, Miguel, additional, Brockow, Knut, additional, Caubet, Jean-Christoph, additional, Cernadas, Josefina Rodrigues, additional, Chiriac, Anca, additional, Demoly, Pascal, additional, Garvey, Lene Heise, additional, Merk, Hans F., additional, Mosbech, Holger, additional, Nakonechna, Alla, additional, and Romano, Antonino, additional

Published
2019
Full Text
View/download PDF

22. Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: A PRISMA‐compliant systematic review—An EAACI position paper.

Author

Oussalah, Abderrahim, Yip, Vincent, Mayorga, Cristobalina, Blanca, Miguel, Barbaud, Annick, Nakonechna, Alla, Cernadas, Josefina, Gotua, Maia, Brockow, Knut, Caubet, Jean‐Christoph, Bircher, Andreas, Atanaskovic‐Markovic, Marina, Demoly, Pascal, Kase‐Tanno, Luciana, Terreehorst, Ingrid, Laguna, José Julio, Romano, Antonino, Guéant, Jean‐Louis, and Pirmohamed, Munir

Subjects
TOXIC epidermal necrolysis, DRUG side effects, HLA histocompatibility antigens, META-analysis, PATHOLOGY, DRUG metabolism, SIDE effects of anticonvulsants, STEVENS-Johnson Syndrome
Abstract

Drug hypersensitivity reactions (DHRs) are associated with high global morbidity and mortality. Cutaneous T cell–mediated reactions classically occur more than 6 hours after drug administration and include life‐threatening conditions such as toxic epidermal necrolysis, Stevens‐Johnson syndrome, and hypersensitivity syndrome. Over the last 20 years, significant advances have been made in our understanding of the pathogenesis of DHRs with the identification of human leukocyte antigens as predisposing factors. This has led to the development of pharmacogenetic screening tests, such as HLA‐B*57:01 in abacavir therapy, which has successfully reduced the incidence of abacavir hypersensitivity reactions. We have completed a PRISMA‐compliant systematic review to identify genetic associations that have been reported in DHRs. In total, 105 studies (5554 cases and 123 548 controls) have been included in the review reporting genetic associations with carbamazepine (n = 31), other aromatic antiepileptic drugs (n = 24), abacavir (n = 11), nevirapine (n = 14), trimethoprim‐sulfamethoxazole (n = 11), dapsone (n = 4), allopurinol (n = 10), and other drugs (n = 5). The most commonly reported genetic variants associated with DHRs are located in human leukocyte antigen genes and genes involved in drug metabolism pathways. Increasing our understanding of genetic variants that contribute to DHRs will allow us to improve diagnosis, develop new treatments, and predict and prevent DHRs in the future. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

23. Management of hypersensitivity reactions to iodinated contrast media

Author

Brockow, Knut, Christiansen, C., Kanny, G., Clément, O., Barbaud, A., Bircher, A., Dewachter, P., Guéant, J. L., Rodriguez Guéant, R. M., Mouton Faivre, C., Ring, J., Romano, A., Sainte Laudy, J., Demoly, P., Pichler, W. J., Aberer, W., Ballmer Weber, B. K., Bilo, M. B., Birnbaum, J., Blanca, M., Blõmecke, B., Campi, P., De Weck, A., Drouet, M., Dzviga, C., Fernandez, J., Gomez, E., Kapp, A., Kidon, M., Kowalski, M., Laroche, D., Mertès, M., Merk, H., Moneret Vautrin, D. A., Pascual Marcos, C., Rebelo Gomes, E., Rueff, F., Sanz, M. L., Torres, M. J., Vervloet, D., Wedi, B., MARONE, GIANNI, Brockow, Knut, Christiansen, C., Kanny, G., Clément, O., Barbaud, A., Bircher, A., Dewachter, P., Guéant, J. L., Rodriguez Guéant, R. M., Mouton Faivre, C., Ring, J., Romano, A., Sainte Laudy, J., Demoly, P., Pichler, W. J., Aberer, W., Ballmer Weber, B. K., Bilo, M. B., Birnbaum, J., Blanca, M., Blõmecke, B., Campi, P., De Weck, A., Drouet, M., Dzviga, C., Fernandez, J., Gomez, E., Kapp, A., Kidon, M., Kowalski, M., Laroche, D., Marone, Gianni, Mertès, M., Merk, H., Moneret Vautrin, D. A., Pascual Marcos, C., Rebelo Gomes, E., Rueff, F., Sanz, M. L., Torres, M. J., Vervloet, D., and Wedi, B.

Subjects
medicine.medical_specialty, Allergy, Premedication, Immunology, Drug Hypersensitivity, Iodinated contrast media, Skin test, Immediate reaction, Prevalence, Immunology and Allergy, Medicine, In patient, Iodine Compound, business.industry, Contrast media, Risk Factor, ALLERGIC/HYPERSENSITIVITY, Nonimmediate reaction, Diagnostic test, medicine.disease, Dermatology, Surgery, Skin reaction, business, Diagnosi, Human
Abstract

All iodinated contrast media (CM) are known to cause both immediate (≤1 h) and nonimmediate (>1 h) hypersensitivity reactions. Although for most immediate reactions an allergic hypersensitivity cannot be demonstrated, recent studies indicate that the severe immediate reactions may be IgE-mediated, while most of the nonimmediate exanthematous skin reactions, appear to be T-cell mediated. Patients who experience such hypersensitivity reactions are therefore advised to undergo an allergologic evaluation. Several investigators have found skin testing to be useful in confirming a CM allergy, especially in patients with nonimmediate skin eruptions. If a patient with confirmed allergy to a CM needs a new CM exposure, a skin test negative CM should be chosen and premedication may be tried. However, none of these precautional measures is a guarantee against a repeat reaction. More research focusing on pathomechanisms, diagnostic testing and premedication is therefore clearly needed in order to prevent CM-induced hypersensitivity reactions in the future.

Published
2005

24. Drug re-challenges in cutaneous adverse drug reactions: information and effectiveness in the long-term management of patients

Author

Jean-Luc Schmutz, Ph Tréchot, A. Barbaud, C. Loos-Ayav, A. C. Bursztejn, C. Pouget-Jasson, and Julie Waton

Subjects
Drug, medicine.medical_specialty, Allergy, business.industry, medicine.drug_class, media_common.quotation_subject, Immunology, Provocation test, Antibiotics, medicine.disease, Group B, Surgery, Acetaminophen, Internal medicine, Immunopathology, medicine, Immunology and Allergy, Corticosteroid, business, medicine.drug, media_common
Abstract

To cite this article: Waton J, Pouget-Jasson C, Loos-Ayav C, Trechot P, Bursztejn AC, Schmutz JL, Barbaud A. Drug re-challenges in cutaneous adverse drug reactions: information and effectiveness in the long term management of patients. Allergy 2011; 66: 941–947. Abstract Background: In patients with cutaneous adverse drug reactions (CADR), drug skin tests and re-challenge under hospital surveillance (RCH) are helpful. The aim of this study was to determine if patients with negative drug RCH can tolerate subsequent treatments with the same drugs. Patients and Methods: Patients with a negative RCH in the last 10 years answered a telephone questionnaire which was delivered by the same investigator in order to determine if subsequently the patients were able to tolerate the drug with which they had a negative RCH and also to study the reasons why the drugs were not taken again. Results: Six hundred and thirty-seven RCH were analyzed (349 patients, mean age 47 years), 134 drugs were taken again (group A) and 359 were not (group B). In group A, 12 reactions occurred in 10 patients (9%). In group B, drugs were not taken again because 76% of the patients evaluated for an intolerance to antibiotics or radiocontrast media did not require a new course of these products or because their general practitioner (GP) did not want to prescribe these drugs. Discussion: Ninety percent of the RCH (88.5% of the patients) with a CADR followed by investigations and a RCH have a good tolerance to subsequent treatment with the RC drug. The mechanisms involved in this intolerance despite negative RCH are discussed. Conclusion: The provocation test procedure, considered as useful by 88% of the patients, has a good negative predictive value. Furthermore, these investigations need to be accompanied by clear information on the patient and his GP.

Published
2011

25. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study

Author

A. Barbaud, Patrizia Bonadonna, E. Tomaz, J. Ring, Gisèle Kanny, E. Faria, Antonino Romano, Werner Aberer, C. Christiansen, J. Rodrigues Cernadas, Knut Brockow, Pascal Demoly, Andreas J. Bircher, Werner J. Pichler, and Marianne Lerch

Subjects
Adult, Male, medicine.medical_specialty, Allergy, Adolescent, Immunology, Contrast Media, Cross Reactions, Sensitivity and Specificity, Drug Hypersensitivity, Iodinated contrast media, Young Adult, medicine, Humans, Immunology and Allergy, In patient, Prospective Studies, Child, Prospective cohort study, Aged, Skin Tests, Aged, 80 and over, business.industry, Skin test, Middle Aged, medicine.disease, Dermatology, Surgery, Contrast medium, Multicenter study, Intradermal test, Female, business, Iodine
Abstract

BACKGROUND: Iodinated contrast media cause both immediate and nonimmediate hypersensitivity reactions. The aim of this prospective study was to determine the specificity and sensitivity of skin tests in patients who have experienced such reactions. METHODS: Skin prick, intradermal and patch tests with a series of contrast media were conducted in 220 patients with either immediate or nonimmediate reaction. Positive skin tests were defined according to internationally accepted guidelines. Seventy-one never-exposed subjects and 11 subjects who had tolerated contrast medium exposure, served as negative controls. RESULTS: Skin test specificity was 96-100%. For tests conducted within the time period from 2 to 6 months after the reaction, up to 50% of immediate reactors and up to 47% of nonimmediate reactors were skin test positive. For immediate reactors, the intradermal tests were the most sensitive, whereas delayed intradermal tests in combination with patch tests were needed for optimal sensitivity in nonimmediate reactors. Contrast medium cross-reactivity was more common in the nonimmediate than in the immediate group. Interestingly, 49% of immediate and 52% of nonimmediate symptoms occurred in previously unexposed patients. Many of these patients were skin test positive, indicating that they were already sensitized at the time of first contrast medium exposure. CONCLUSIONS: These data suggest that at least 50% of hypersensitivity reactions to contrast media are caused by an immunological mechanism. Skin testing appears to be a useful tool for diagnosis of contrast medium allergy and may play an important role in selection of a safe product in previous reactors.

Published
2009

26. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GA2LEN platform. The Galenda project

Author

E. Van Ganse, Marina Atanaskovic-Markovic, Nikolaos G. Papadopoulos, P.M. Mertes, Philippe-Jean Bousquet, Andreas J. Bircher, A. Sidoroff, A. Bijl, Maria L. Sanz, Hans F. Merk, A. Barbaud, Eva Rebelo Gomes, Claude Ponvert, Marek L. Kowalski, M. Blanca, Silvia Caimmi, Knut Brockow, Antonino Romano, Jean-Pierre Daurès, G.W. Canonica, Andrzej Szczeklik, M.J. Torres, B. Sachs, Javier Fernández, Ewa Nizankowska-Mogilnicka, T. Zuberbier, Werner J. Pichler, Pascal Demoly, A.L. de Weck, Violeta Kvedariene, P. Martins, Barbro Dahlén, Patrizia Bonadonna, Josefina Cernadas, Munir Pirmohamed, Werner Aberer, Ingrid Terreehorst, M. Salapatas, B. Arnoux, Peter Burney, Jean-Louis Guéant, and J. Ring

Subjects
Allergy, Clinical immunology, Database, business.industry, Operating procedures, Immunology, Drug allergy, MEDLINE, medicine.disease, computer.software_genre, Spontaneous reporting, Pharmacovigilance, medicine, Immunology and Allergy, Drug reaction, business, computer
Abstract

Nonallergic hypersensitivity and allergic reactions are part of the many different types of adverse drug reactions (ADRs). Databases exist for the collection of ADRs. Spontaneous reporting makes up the core data-generating system of pharmacovigilance, but there is a large under-estimation of allergy/hypersensitivity drug reactions. A specific database is therefore required for drug allergy and hypersensitivity using standard operating procedures (SOPs), as the diagnosis of drug allergy/hypersensitivity is difficult and current pharmacovigilance algorithms are insufficient. Although difficult, the diagnosis of drug allergy/hypersensitivity has been standardized by the European Network for Drug Allergy (ENDA) under the aegis of the European Academy of Allergology and Clinical Immunology and SOPs have been published. Based on ENDA and Global Allergy and Asthma European Network (GA(2)LEN, EU Framework Programme 6) SOPs, a Drug Allergy and Hypersensitivity Database (DAHD((R))) has been established under FileMaker((R)) Pro 9. It is already available online in many different languages and can be accessed using a personal login. GA(2)LEN is a European network of 27 partners (16 countries) and 59 collaborating centres (26 countries), which can coordinate and implement the DAHD across Europe. The GA(2)LEN-ENDA-DAHD platform interacting with a pharmacovigilance network appears to be of great interest for the reporting of allergy/hypersensitivity ADRs in conjunction with other pharmacovigilance instruments.

Published
2009

27. Allergological workup with half‐dose challenge in iodinated contrast media hypersensitivity.

Author

Soria, Angèle, Masson, Nathalie, Vial‐Dupuy, Amandine, Gaouar, Hafida, Amsler, Emmanuelle, Chollet‐Martin, Sylvie, Nicaise‐Roland, Pascale, Autegarden, Jean‐Eric, and Barbaud, Annick

Subjects
RADIOGRAPHIC contrast media, ALLERGIES, ANTIALLERGIC agents
Abstract

The article offers information on the diagnosis of hypersensitivity reaction (HSR) to iodinated contrast media (ICM) is challenging when based on clinical history and skin tests. It mentions the objective of this study was to determine the negative predictive value (NPV) for skin tests as compared with the intravenous provocation tests (IPT) 50 mL; and also mentions the IPT was reduced to 10 mL with glomerular filtration rate (GFR).

Published
2019
Full Text
View/download PDF

28. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity.

Author

Brockow, Knut, Ardern‐Jones, Michael R., Mockenhaupt, Maja, Aberer, Werner, Barbaud, Annick, Caubet, Jean‐Christoph, Spiewak, Radoslaw, Torres, María José, and Mortz, Charlotte G.

Subjects
SKIN inflammation, SKIN disease treatment, TRANSDERMAL medication, ALLERGIES, IMMUNOLOGIC diseases
Abstract

Drug hypersensitivity reactions (DHRs) are common, and the skin is by far the most frequently involved organ with a broad spectrum of reaction types. The diagnosis of cutaneous DHRs (CDHR) may be difficult because of multiple differential diagnoses. A correct classification is important for the correct diagnosis and management. With these guidelines, we aim to give precise definitions and provide the background needed for doctors to correctly classify CDHR. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

29. Sensitization to petrolatum: an unusual cause of false-positive drug patch-tests

Author

A. Barbaud, Jean-Luc Schmutz, G. Ulrich, Ph Tréchot, and N. Commun

Subjects
Drug, medicine.medical_specialty, Petrolatum, media_common.quotation_subject, Immunology, Dermatitis, Contact, Cosmetics, Dosage form, Vaseline, medicine, Humans, Immunology and Allergy, False Positive Reactions, Drug reaction, White petrolatum, Sensitization, media_common, business.industry, Middle Aged, Patch Tests, Dermatology, Drug patch, medicine.drug_formulation_ingredient, medicine.anatomical_structure, Female, business
Abstract

We report on an unexpected sensitization to petrolatum diagnosed with the occurrence of multiple nonrelevant and false-positive drug patch-tests performed while investigating a patient suffering from many cutaneous adverse drug reactions. All the positive drug patch-tests were prepared with GILBERT vaseline. This petrolatum reaction is positive as it was tested with five other brands of petrolatums a few months later. As the same petrolatums, but from different batches were tested, patch-tests with GILBERT petrolatum were doubtful, while other petrolatums were positive. White petrolatum is a mixture of semisolid hydrocarbons of the methane series. The sensitizing impurities of petrolatum are polycyclic aromatic hydrocarbons, e.g. phenanthrene derivatives. The purity of petrolatum depends on both the petroleum stock and on the production and packaging methods. Even if rare, contact sensitization to petrolatum can disturb the interpretation of drug patch-tests. It is necessary in the interpretation of drug patch-tests to test both in petrolatum and other vehicles and with all the different petrolatums used in preparing the material for drug patch-tests. So, it is essential to advise the patients sensitized to petrolatum to remove all the topical drugs, such as all the cosmetics, which contain petrolatum in their formulation.

Published
2004

31. Allergy to betalactams and nucleotide-binding oligomerization domain (NOD) gene polymorphisms

Author

A. Barbaud, JA Cornejo, Jean-Louis Guéant, M. Blanca, Francesco Gaeta, Abderrahim Oussalah, I Gastin, Antonino Romano, AC Bursztejn, Rosa-Maria Guéant-Rodriguez, Céline Chéry, Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Complesso Integrato Columbus, Istituto di Ricovero e Cura a Carattere Scientifico [Troina, Italy] (IRCCS), Oasi Maria Santissima Srl [Troina, Italy], Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Allergy Service [Carlos Haya Hospital], and Hospital Regional Universitario Carlos Haya

Subjects
Adult, Male, Allergy, [SDV]Life Sciences [q-bio], Immunology, Nod2 Signaling Adaptor Protein, Nod, Biology, Immunoglobulin E, beta-Lactams, betalactam allergy, polymorphism, Atopy, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Genetic, NOD2, Nod1 Signaling Adaptor Protein, Genotype, medicine, Hypersensitivity, Immunology and Allergy, Humans, Allele, 030304 developmental biology, Genetics, Inflammation, 0303 health sciences, Polymorphism, Genetic, Settore MED/09 - MEDICINA INTERNA, Case-control study, Allergens, Middle Aged, medicine.disease, NOD gene, digestive system diseases, 030228 respiratory system, Case-Control Studies, biology.protein, Female, IgE
Abstract

Background Polymorphisms of interleukin genes related to IgE production and inflammation are predictors of hypersensitivity to betalactam, but nothing is known on the influence of NOD genes, despite their association with inflammation and atopy. Objective To evaluate the association of NOD2 and NOD1 polymorphisms with betalactam allergy. Method We genotyped 3 polymorphisms of NOD2 and 1 of NOD1 in 368 Italian and 387 Spanish patients, compared with 368 and 326 controls, respectively. Results CT/TT genotypes of rs2066845 of NOD2 predicted a lower risk in Italy (P = 0.003), while WT/insC genotype of rs5743293 (also in leucine-rich repeat domain) predicted a higher risk in Spain (P = 0.007). G allele of rs2066845 was associated with a higher level of IgE in the Italian population. Conclusion The mirrored influence of these NOD2 polymorphisms on betalactam allergy in two populations suggests a link with pathways of inflammation and/or atopy through mechanisms, which need to be clarified.

Published
2013

32. Drug-induced lichenoid reaction after kyphoplasty

Author

M, Weinborn, J, Waton, D, Roch, J L, Schmutz, and A, Barbaud

Subjects
Male, Lichenoid Eruptions, Bone Cements, Humans, Kyphoplasty, Methylmethacrylate, Aged, Skin Tests
Published
2011

33. Drug re-challenges in cutaneous adverse drug reactions: information and effectiveness in the long-term management of patients

Author

J, Waton, C, Pouget-Jasson, C, Loos-Ayav, P, Trechot, A C, Bursztejn, J L, Schmutz, and A, Barbaud

Subjects
Male, Time Factors, Drug-Related Side Effects and Adverse Reactions, Middle Aged, Administration, Cutaneous, Anti-Bacterial Agents, Drug Hypersensitivity, Treatment Outcome, Pharmaceutical Preparations, Surveys and Questionnaires, Humans, Female, Drug Eruptions, Skin Tests
Abstract

In patients with cutaneous adverse drug reactions (CADR), drug skin tests and re-challenge under hospital surveillance (RCH) are helpful. The aim of this study was to determine if patients with negative drug RCH can tolerate subsequent treatments with the same drugs.Patients with a negative RCH in the last 10 years answered a telephone questionnaire which was delivered by the same investigator in order to determine if subsequently the patients were able to tolerate the drug with which they had a negative RCH and also to study the reasons why the drugs were not taken again.Six hundred and thirty-seven RCH were analyzed (349 patients, mean age 47 years), 134 drugs were taken again (group A) and 359 were not (group B). In group A, 12 reactions occurred in 10 patients (9%). In group B, drugs were not taken again because 76% of the patients evaluated for an intolerance to antibiotics or radiocontrast media did not require a new course of these products or because their general practitioner (GP) did not want to prescribe these drugs.Ninety percent of the RCH (88.5% of the patients) with a CADR followed by investigations and a RCH have a good tolerance to subsequent treatment with the RC drug. The mechanisms involved in this intolerance despite negative RCH are discussed. The provocation test procedure, considered as useful by 88% of the patients, has a good negative predictive value. Furthermore, these investigations need to be accompanied by clear information on the patient and his GP.

Published
2011

34. Cutaneous adverse drug reaction induced by a generic substitute of Zyloric with a residual sensitization to allopurinol

Author

A. Barbaud, M.L. Chandeclerc, Jean-Luc Schmutz, S. Martin, Ph Tréchot, and F. Weber-Muller

Subjects
Male, Parapsoriasis, business.industry, Allopurinol, Immunology, Pharmacology, Middle Aged, medicine.disease, Drug Hypersensitivity, medicine.anatomical_structure, medicine, Immunology and Allergy, Drugs, Generic, Humans, business, Sensitization, Adverse drug reaction, medicine.drug
Published
2006

35. Maculopapular rash induced by diltiazem: allergological investigations in four patients and cross reactions between calcium channel blockers

Author

G. Faure, A. Barbaud, Ph Tréchot, C Cholez, J.-L. Schmutz, and M.-C. Bene

Subjects
Male, business.industry, Calcium channel, Immunology, Cross reactions, Cross Reactions, Middle Aged, Calcium Channel Blockers, Drug Hypersensitivity, Diltiazem, Anesthesia, Maculopapular rash, Immunology and Allergy, Medicine, Humans, Female, Drug Eruptions, medicine.symptom, business, medicine.drug, Skin Tests
Published
2003

37. Genetic variants associated with drugs-induced immediate hypersensitivity reactions: a PRISMA-compliant systematic review.

Author

Oussalah, A., Mayorga, C., Blanca, M., Barbaud, A., Nakonechna, A., Cernadas, J., Gotua, M., Brockow, K., Caubet, J.‐C., Bircher, A., Atanaskovic, M., Demoly, P., K. Tanno, L., Terreehorst, I., Laguna, J. J., Romano, A., and Guéant, J.‐L.

Subjects
DRUG allergy, IMMUNOGLOBULIN E, BETA lactam antibiotics, NONSTEROIDAL anti-inflammatory agents, ASPIRIN, GENETICS
Abstract

Drug hypersensitivity includes allergic ( AR) and nonallergic reactions ( NARs) influenced by genetic predisposition. We performed a systematic review of genetic predictors of IgE-mediated AR and NAR with MEDLINE and PubMed search engine between January 1966 and December 2014. Among 3110 citations, the search selected 53 studies, 42 of which remained eligible. These eligible studies have evaluated genetic determinants of immediate reactions ( IR) to beta-lactams ( n = 19), NAR against aspirin ( n = 12) and other nonsteroidal anti-inflammatory drugs ( NSAIDs) ( n = 8), and IR to biologics ( n = 3). We reported two genomewide association studies and four case-control studies on candidate genes validated by replication. Genes involved in IR to beta-lactams belonged to HLA type 2 antigen processing, IgE production, atopy, and inflammation, including 4 genes validated by replications, HLA- DRA, ILR4, NOD2, and LGALS3. Genes involved in NAR to aspirin belonged to arachidonic acid pathway, membrane-spanning 4A gene family, histamine production pathway, and pro-inflammatory cytokines, while those involved in NAR to all NSAIDs belonged to arachidonic acid pathway and HLA antigen processing pathway. ALOX5 was a common predictor of studies on NAR to both aspirin and NSAIDs. Although these first conclusions could be drawn, this review highlights also the lack of reliable data and the need for replicating studies in contrasted populations, taking into account worldwide allele frequencies, gene-gene interactions, and contrasted situations of environmental exposure. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

43. Skin test concentrations for systemically administered drugs - an ENDA/ EAACI Drug Allergy Interest Group position paper.

Author

Brockow, K., Garvey, L. H., Aberer, W., Atanaskovic‐Markovic, M., Barbaud, A., Bilo, M. B., Bircher, A., Blanca, M., Bonadonna, B., Campi, P., Castro, E., Cernadas, J. R., Chiriac, A. M., Demoly, P., Grosber, M., Gooi, J., Lombardo, C., Mertes, P. M., Mosbech, H., and Nasser, S.

Subjects
DRUG allergy, SKIN tests, DRUG administration, MEDICAL practice, BETA lactam antibiotics, HEPARIN, CLINICAL immunology, MEDICAL publishing, DIAGNOSIS
Abstract

Skin tests are of paramount importance for the evaluation of drug hypersensitivity reactions. Drug skin tests are often not carried out because of lack of concise information on specific test concentrations. The diagnosis of drug allergy is often based on history alone, which is an unreliable indicator of true hypersensitivity.To promote and standardize reproducible skin testing with safe and nonirritant drug concentrations in the clinical practice, the European Network and European Academy of Allergy and Clinical Immunology ( EAACI) Interest Group on Drug Allergy has performed a literature search on skin test drug concentration in MEDLINE and EMBASE, reviewed and evaluated the literature in five languages using the GRADE system for quality of evidence and strength of recommendation. Where the literature is poor, we have taken into consideration the collective experience of the group.We recommend drug concentration for skin testing aiming to achieve a specificity of at least 95%. It has been possible to recommend specific drug concentration for betalactam antibiotics, perioperative drugs, heparins, platinum salts and radiocontrast media. For many other drugs, there is insufficient evidence to recommend appropriate drug concentration. There is urgent need for multicentre studies designed to establish and validate drug skin test concentration using standard protocols. For most drugs, sensitivity of skin testing is higher in immediate hypersensitivity compared to nonimmediate hypersensitivity. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

44. Skin testing in patients with hypersensitivity reactions to iodinated contrast media – a European multicenter study.

Author

Brockow, K., Romano, A., Aberer, W., Bircher, A. J., Barbaud, A., Bonadonna, P., Faria, E., Kanny, G., Lerch, M., Pichler, W. J., Ring, J., Cernadas, J. Rodrigues, Tomaz, E., Demoly, P., and Christiansen, C.

Subjects
SKIN tests, ALLERGIES, ANAPHYLAXIS, CONTRAST media, MEDICAL radiography exposure
Abstract

Background: Iodinated contrast media cause both immediate and nonimmediate hypersensitivity reactions. The aim of this prospective study was to determine the specificity and sensitivity of skin tests in patients who have experienced such reactions. Methods: Skin prick, intradermal and patch tests with a series of contrast media were conducted in 220 patients with either immediate or nonimmediate reaction. Positive skin tests were defined according to internationally accepted guidelines. Seventy-one never-exposed subjects and 11 subjects who had tolerated contrast medium exposure, served as negative controls. Results: Skin test specificity was 96–100%. For tests conducted within the time period from 2 to 6 months after the reaction, up to 50% of immediate reactors and up to 47% of nonimmediate reactors were skin test positive. For immediate reactors, the intradermal tests were the most sensitive, whereas delayed intradermal tests in combination with patch tests were needed for optimal sensitivity in nonimmediate reactors. Contrast medium cross-reactivity was more common in the nonimmediate than in the immediate group. Interestingly, 49% of immediate and 52% of nonimmediate symptoms occurred in previously unexposed patients. Many of these patients were skin test positive, indicating that they were already sensitized at the time of first contrast medium exposure. Conclusions: These data suggest that at least 50% of hypersensitivity reactions to contrast media are caused by an immunological mechanism. Skin testing appears to be a useful tool for diagnosis of contrast medium allergy and may play an important role in selection of a safe product in previous reactors. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

45. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA–DAHD database and the GA2LEN platform. The Galenda project.

Author

Bousquet, P.-J., Demoly, P., Romano, A., Aberer, W., Bircher, A., Blanca, M., Brockow, K., Pichler, W., Torres, M. J., Terreehorst, I., Arnoux, B., Atanaskovic-Markovic, M., Barbaud, A., Bijl, A., Bonadonna, P., Burney, P. G., Caimmi, S., Canonica, G. W., Cernadas, J., and Dahlen, B.

Subjects
DRUG administration, DRUG side effects, DRUG allergy, DATABASES
Abstract

Nonallergic hypersensitivity and allergic reactions are part of the many different types of adverse drug reactions (ADRs). Databases exist for the collection of ADRs. Spontaneous reporting makes up the core data-generating system of pharmacovigilance, but there is a large under-estimation of allergy/hypersensitivity drug reactions. A specific database is therefore required for drug allergy and hypersensitivity using standard operating procedures (SOPs), as the diagnosis of drug allergy/hypersensitivity is difficult and current pharmacovigilance algorithms are insufficient. Although difficult, the diagnosis of drug allergy/hypersensitivity has been standardized by the European Network for Drug Allergy (ENDA) under the aegis of the European Academy of Allergology and Clinical Immunology and SOPs have been published. Based on ENDA and Global Allergy and Asthma European Network (GA2LEN, EU Framework Programme 6) SOPs, a Drug Allergy and Hypersensitivity Database (DAHD®) has been established under FileMaker® Pro 9. It is already available online in many different languages and can be accessed using a personal login. GA2LEN is a European network of 27 partners (16 countries) and 59 collaborating centres (26 countries), which can coordinate and implement the DAHD across Europe. The GA2LEN–ENDA–DAHD platform interacting with a pharmacovigilance network appears to be of great interest for the reporting of allergy/hypersensitivity ADRs in conjunction with other pharmacovigilance instruments. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

46. ALLERGY Net Maculopapular rash induced by diltiazem: allergological investigations in four patients and cross reactions between calcium channel blockers.

Author

Cholez, C., Trechot, P., Schmutz, J.-L., Faure, G., Bene, M.-C., and Barbaud, A.

Subjects
CALCIUM antagonists, SKIN tests, PATCH-clamp techniques (Electrophysiology), CROSS reactions (Immunology)
Abstract

Examines the value of patch tests (PT) and cross reactions among calcium channel blockers (CCB) by performing drug skin tests in four patients who had developed a maculopapular rash (MPR) eight to 12 days after the beginning of a treatment with diltiazem. Suggested guidelines following the division of CCB into dihydropyridines and nondihydropyridines.

Published
2003
Full Text
View/download PDF

47. Cutaneous adverse drug reaction induced by a generic substitute of Zyloric® with a residual sensitization to allopurinol.

Author

Chandeclerc, M.-L., Tréchot, P., Martin, S., Weber-Muller, F., Schmutz, J.-L., and Barbaud, A.

Subjects
DRUG side effects, GENERIC drugs, EXCIPIENTS, PATIENTS, GENERIC drug substitution
Abstract

The article discusses cutaneous adverse drug reaction (CADR) caused by a substitute of generic drugs. Generic drugs have activity compounds that are similar to original drugs but their excipients can be different from quality and quantity. These excipients are responsible for CADR on patients. Information on the first case of CADR that occurred to a patient who had taken Zyloric pills is provided.

Published
2006
Full Text
View/download PDF

48. Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper.

Author

Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, Bircher A, Blanca M, Bonadonna B, Campi P, Castro E, Cernadas JR, Chiriac AM, Demoly P, Grosber M, Gooi J, Lombardo C, Mertes PM, Mosbech H, Nasser S, Pagani M, Ring J, Romano A, Scherer K, Schnyder B, Testi S, Torres M, Trautmann A, and Terreehorst I

Subjects
Humans, Sensitivity and Specificity, Drug Hypersensitivity diagnosis, Hypersensitivity, Delayed diagnosis, Hypersensitivity, Immediate diagnosis, Skin Tests methods
Abstract

Skin tests are of paramount importance for the evaluation of drug hypersensitivity reactions. Drug skin tests are often not carried out because of lack of concise information on specific test concentrations. The diagnosis of drug allergy is often based on history alone, which is an unreliable indicator of true hypersensitivity.To promote and standardize reproducible skin testing with safe and nonirritant drug concentrations in the clinical practice, the European Network and European Academy of Allergy and Clinical Immunology (EAACI) Interest Group on Drug Allergy has performed a literature search on skin test drug concentration in MEDLINE and EMBASE, reviewed and evaluated the literature in five languages using the GRADE system for quality of evidence and strength of recommendation. Where the literature is poor, we have taken into consideration the collective experience of the group.We recommend drug concentration for skin testing aiming to achieve a specificity of at least 95%. It has been possible to recommend specific drug concentration for betalactam antibiotics, perioperative drugs, heparins, platinum salts and radiocontrast media. For many other drugs, there is insufficient evidence to recommend appropriate drug concentration. There is urgent need for multicentre studies designed to establish and validate drug skin test concentration using standard protocols. For most drugs, sensitivity of skin testing is higher in immediate hypersensitivity compared to nonimmediate hypersensitivity., (© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2013
Full Text
View/download PDF

49. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project.

Author

Bousquet PJ, Demoly P, Romano A, Aberer W, Bircher A, Blanca M, Brockow K, Pichler W, Torres MJ, Terreehorst I, Arnoux B, Atanaskovic-Markovic M, Barbaud A, Bijl A, Bonadonna P, Burney PG, Caimmi S, Canonica GW, Cernadas J, Dahlen B, Daures JP, Fernandez J, Gomes E, Gueant JL, Kowalski ML, Kvedariene V, Mertes PM, Martins P, Nizankowska-Mogilnicka E, Papadopoulos N, Ponvert C, Pirmohamed M, Ring J, Salapatas M, Sanz ML, Szczeklik A, Van Ganse E, De Weck AL, Zuberbier T, Merk HF, Sachs B, and Sidoroff A

Subjects
Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents immunology, Drug Hypersensitivity immunology, Humans, Surveys and Questionnaires, beta-Lactams adverse effects, beta-Lactams immunology, Adverse Drug Reaction Reporting Systems organization & administration, Databases, Factual, Drug Hypersensitivity diagnosis, Drug Hypersensitivity epidemiology, Drug Information Services organization & administration
Abstract

Nonallergic hypersensitivity and allergic reactions are part of the many different types of adverse drug reactions (ADRs). Databases exist for the collection of ADRs. Spontaneous reporting makes up the core data-generating system of pharmacovigilance, but there is a large under-estimation of allergy/hypersensitivity drug reactions. A specific database is therefore required for drug allergy and hypersensitivity using standard operating procedures (SOPs), as the diagnosis of drug allergy/hypersensitivity is difficult and current pharmacovigilance algorithms are insufficient. Although difficult, the diagnosis of drug allergy/hypersensitivity has been standardized by the European Network for Drug Allergy (ENDA) under the aegis of the European Academy of Allergology and Clinical Immunology and SOPs have been published. Based on ENDA and Global Allergy and Asthma European Network (GA(2)LEN, EU Framework Programme 6) SOPs, a Drug Allergy and Hypersensitivity Database (DAHD((R))) has been established under FileMaker((R)) Pro 9. It is already available online in many different languages and can be accessed using a personal login. GA(2)LEN is a European network of 27 partners (16 countries) and 59 collaborating centres (26 countries), which can coordinate and implement the DAHD across Europe. The GA(2)LEN-ENDA-DAHD platform interacting with a pharmacovigilance network appears to be of great interest for the reporting of allergy/hypersensitivity ADRs in conjunction with other pharmacovigilance instruments.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results